Potential Dual Role of Eugenol in Inhibiting Advanced Glycation End Products in Diabetes: Proteomic and Mechanistic Insights
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Medicinally important genus Ocimum harbors a vast pool of chemically diverse metabolites. Current study aims at identifying anti-diabetic candidate compounds from Ocimum species. Major metabolites in O. kilimandscharicum, O. tenuiflorum, O. gratissimum were purified, characterized and evaluated for anti-glycation activity. In vitro inhibition of advanced glycation end products (AGEs) by eugenol was found to be highest. Preliminary biophysical analysis and blind docking studies to understand eugenol-albumin interaction indicated eugenol to possess strong binding affinity for surface exposed lysines. However, binding of eugenol to bovine serum albumin (BSA) did not result in significant change in secondary structure of protein. In vivo diabetic mice model studies with eugenol showed reduction in blood glucose levels by 38% likely due to inhibition of α-glucosidase while insulin and glycated hemoglobin levels remain unchanged. Western blotting using anti-AGE antibody and mass spectrometry detected notably fewer AGE modified peptides upon eugenol treatment both in vivo and in vitro. Histopathological examination revealed comparatively lesser lesions in eugenol-treated mice. Thus, we propose eugenol has dual mode of action in combating diabetes; it lowers blood glucose by inhibiting α-glucosidase and prevents AGE formation by binding to ε-amine group on lysine, protecting it from glycation, offering potential use in diabetic management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fukaya, N., Mochizuki, K., Tanaka, Y., Kumazawa, T., Jiuxin, Z., Fuchigami, M., & Goda, T. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.048 · Cited by 30
Cited by
Natural products for the treatment of type 2 diabetes mellitus: Pharmacology and mechanisms
Xu, L., Li, Y., Dai, Y., & Peng, J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.015 · Cited by 452
Essential oil eugenol: Sources, extraction techniques and nutraceutical perspectives
Khalil, A. A., Rahman, U. U., Khan, M. R., Sahar, A., Mehmood, T., & Khan, M. (2017) · RSC Advances · doi:10.1039/c7ra04803c · Cited by 407
“Furthermore, Singh et al. 88 proposed dual anti-diabetic mechanism of eugenol; primarily by inhibiting alpha-glucosidases followed by preventing formation of advanced glycation end products (AGE).”
BackgroundPrzeor, M. (2022) · Pharmaceuticals · doi:10.3390/ph15010065 · Cited by 93
Gurav, T. P., Dholakia, B. B., & Giri, A. P. (2022) · Phytochemistry Reviews · doi:10.1007/s11101-021-09767-z · Cited by 87
“…antidiabetic, anticancer, radiation protective, anti-hyperlipidemic activities, etc. (Ali et al. 2021; Pandey et al. 2014; Purushothaman et al. 2018; Santos et al. 2021; Singh and Chaudhuri 2018; Singh et al. 2015, 2016), whereas essential oil is valued in aromatherapy (Li and Chang 2016).”
BackgroundSelf-citation
Metadata
- Authors
- Singh, P., Jayaramaiah, R. H., Agawane, S. B., Vannuruswamy, G., Korwar, A. M., Anand, A., Dhaygude, V. S., Shaikh, M. L., Joshi, R. S., Boppana, R., Kulkarni, M. J., Thulasiram, H. V., & Giri, A. P.
- Venue
- Scientific Reports
- Published
- 2016-01-07
- Volume
- 6
- Issue
- 1
- Pages
- 18798-18798
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2225072053
- Cited by
- 139
- References
- 1
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential Dual Role of Eugenol in Inhibiting Advanced Glycation End Products in Diabetes: Proteomic and Mechanistic Insights. https://app.cochat.ai/papers/10.1038/srep18798
- The paper
- Singh, P., Jayaramaiah, R. H., Agawane, S. B., Vannuruswamy, G., Korwar, A. M., Anand, A., Dhaygude, V. S., Shaikh, M. L., Joshi, R. S., Boppana, R., Kulkarni, M. J., Thulasiram, H. V., & Giri, A. P. (2016). Potential Dual Role of Eugenol in Inhibiting Advanced Glycation End Products in Diabetes: Proteomic and Mechanistic Insights. Scientific Reports. https://doi.org/10.1038/srep18798
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.